KR101937501B1 - 치환된 2,3-디히드로이미다조[1,2-ｃ]퀴나졸린 염 - Google Patents

치환된 2,3-디히드로이미다조[1,2-ｃ]퀴나졸린 염 Download PDF

Info

Publication number
KR101937501B1
KR101937501B1 KR1020137028852A KR20137028852A KR101937501B1 KR 101937501 B1 KR101937501 B1 KR 101937501B1 KR 1020137028852 A KR1020137028852 A KR 1020137028852A KR 20137028852 A KR20137028852 A KR 20137028852A KR 101937501 B1 KR101937501 B1 KR 101937501B1
Authority
KR
South Korea
Prior art keywords
cancer
pegylated pegylated
mixture
acid
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137028852A
Other languages
English (en)
Korean (ko)
Other versions
KR20140021637A (ko
Inventor
얀 게오르그 피터스
한스-크리스티안 밀리처
하르트비크 뮐러
Original Assignee
바이엘 인텔렉쳐 프로퍼티 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43984137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101937501(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이엘 인텔렉쳐 프로퍼티 게엠베하 filed Critical 바이엘 인텔렉쳐 프로퍼티 게엠베하
Publication of KR20140021637A publication Critical patent/KR20140021637A/ko
Application granted granted Critical
Publication of KR101937501B1 publication Critical patent/KR101937501B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137028852A 2011-04-05 2012-03-29 치환된 2,3-디히드로이미다조[1,2-ｃ]퀴나졸린 염 Expired - Fee Related KR101937501B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11161111A EP2508525A1 (en) 2011-04-05 2011-04-05 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP11161111.7 2011-04-05
PCT/EP2012/055600 WO2012136553A1 (en) 2011-04-05 2012-03-29 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Publications (2)

Publication Number Publication Date
KR20140021637A KR20140021637A (ko) 2014-02-20
KR101937501B1 true KR101937501B1 (ko) 2019-01-10

Family

ID=43984137

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137028852A Expired - Fee Related KR101937501B1 (ko) 2011-04-05 2012-03-29 치환된 2,3-디히드로이미다조[1,2-ｃ]퀴나졸린 염

Country Status (42)

Country Link
US (2) US10383876B2 (https=)
EP (2) EP2508525A1 (https=)
JP (2) JP5763834B2 (https=)
KR (1) KR101937501B1 (https=)
CN (1) CN103649091B (https=)
AP (1) AP3709A (https=)
AR (1) AR085718A1 (https=)
AU (1) AU2012238891B2 (https=)
BR (1) BR112013025549A2 (https=)
CA (1) CA2832123C (https=)
CL (1) CL2013002870A1 (https=)
CO (1) CO6781534A2 (https=)
CR (1) CR20130511A (https=)
CU (1) CU24208B1 (https=)
CY (1) CY1116231T1 (https=)
DK (1) DK2694508T3 (https=)
DO (1) DOP2013000223A (https=)
EA (1) EA023646B1 (https=)
EC (1) ECSP13013006A (https=)
ES (1) ES2529653T3 (https=)
GT (1) GT201300234A (https=)
HR (1) HRP20150138T1 (https=)
IL (1) IL228561A (https=)
JO (1) JO2958B1 (https=)
MA (1) MA35014B1 (https=)
ME (1) ME02021B (https=)
MX (1) MX336057B (https=)
MY (1) MY169452A (https=)
PE (1) PE20141038A1 (https=)
PH (1) PH12013502065A1 (https=)
PL (1) PL2694508T3 (https=)
PT (1) PT2694508E (https=)
RS (1) RS53811B1 (https=)
SG (1) SG193595A1 (https=)
SI (1) SI2694508T1 (https=)
SM (1) SMT201500037B (https=)
TN (1) TN2013000401A1 (https=)
TW (2) TWI592158B (https=)
UA (1) UA111604C2 (https=)
UY (1) UY33985A (https=)
WO (1) WO2012136553A1 (https=)
ZA (1) ZA201307105B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
CU24400B1 (es) 2013-04-08 2019-04-04 Bayer Pharma AG Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
BR112015029953A2 (pt) 2013-06-14 2017-09-26 Bayer Pharma AG anticorpos anti-tweakr e seus usos
CN103694319B (zh) * 2013-12-20 2018-02-27 深圳翰宇药业股份有限公司 一种布舍瑞林的纯化方法
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
WO2016142312A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
PE20171790A1 (es) 2015-03-23 2017-12-28 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
BR112018015783A2 (pt) 2016-02-01 2018-12-26 Bayer Pharma AG biomarcadores de copanlisibe
WO2017134000A1 (en) 2016-02-01 2017-08-10 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
PE20231050A1 (es) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
US10844066B2 (en) 2016-03-08 2020-11-24 Bayer Pharma Aktiengesellschaft 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2018112176A1 (en) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
US11684672B2 (en) 2017-02-24 2023-06-27 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-PD-1 antibody
WO2019002068A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
HUE063178T2 (hu) 2017-09-08 2023-12-28 Bayer Pharma AG Kopanlizib formulációi
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
WO2020078788A1 (en) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
AU2019360377A1 (en) 2018-10-17 2021-04-29 Sandoz Ag Co-crystals comprising levothyroxine and a dicarboxylic acid
EP3903786A4 (en) * 2018-12-27 2022-09-28 Holosmedic NEW COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THEM FOR ENHANCING ANTICANCER ACTIVITY
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts
CN121843719A (zh) * 2023-09-08 2026-04-10 法罗斯根有限公司 在制备抗癌剂前药偶联物中回收和去除钯的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605550A5 (https=) 1972-06-08 1978-09-29 Research Corp
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TW225528B (https=) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
ATE411996T1 (de) 2002-09-30 2008-11-15 Bayer Healthcare Ag Kondensierte azolpyrimidinderivate
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2713388C (en) 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
EA201201414A8 (ru) 2010-04-16 2013-12-30 Байер Интеллектчуал Проперти Гмбх КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CU24400B1 (es) 2013-04-08 2019-04-04 Bayer Pharma AG Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
US10117874B2 (en) 2013-12-03 2018-11-06 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
WO2016142312A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Also Published As

Publication number Publication date
CA2832123C (en) 2018-09-11
GT201300234A (es) 2015-01-16
AR085718A1 (es) 2013-10-23
CN103649091B (zh) 2016-06-22
SG193595A1 (en) 2013-10-30
UA111604C2 (uk) 2016-05-25
EA201391470A1 (ru) 2014-03-31
US10383876B2 (en) 2019-08-20
TN2013000401A1 (en) 2015-03-30
EP2508525A1 (en) 2012-10-10
ES2529653T3 (es) 2015-02-24
JP2015164936A (ja) 2015-09-17
TWI549954B (zh) 2016-09-21
DK2694508T3 (en) 2015-02-16
JP5826961B2 (ja) 2015-12-02
TW201637656A (zh) 2016-11-01
IL228561A (en) 2015-10-29
EP2694508A1 (en) 2014-02-12
AU2012238891B2 (en) 2016-12-01
AU2012238891A1 (en) 2013-10-24
US20160193219A1 (en) 2016-07-07
EP2694508B1 (en) 2014-11-19
PL2694508T3 (pl) 2015-04-30
HRP20150138T1 (hr) 2015-05-08
ZA201307105B (en) 2014-11-26
CN103649091A (zh) 2014-03-19
SMT201500037B (it) 2015-05-05
EA023646B1 (ru) 2016-06-30
CU24208B1 (es) 2016-11-29
ME02021B (me) 2015-05-20
AP2013007219A0 (en) 2013-10-31
CL2013002870A1 (es) 2014-06-20
PH12013502065A1 (en) 2016-06-29
BR112013025549A2 (pt) 2016-12-27
CO6781534A2 (es) 2013-10-31
IL228561A0 (en) 2013-12-31
PT2694508E (pt) 2015-02-10
MA35014B1 (fr) 2014-04-03
CY1116231T1 (el) 2017-02-08
HK1195907A1 (zh) 2014-11-28
KR20140021637A (ko) 2014-02-20
US20140072529A1 (en) 2014-03-13
AP3709A (en) 2016-05-31
TW201249847A (en) 2012-12-16
JP2014510119A (ja) 2014-04-24
PE20141038A1 (es) 2014-09-05
JP5763834B2 (ja) 2015-08-12
NZ616198A (en) 2015-09-25
RS53811B1 (sr) 2015-06-30
DOP2013000223A (es) 2013-11-15
SI2694508T1 (sl) 2015-03-31
CR20130511A (es) 2013-12-04
CU20130133A7 (es) 2014-01-29
TWI592158B (zh) 2017-07-21
US9636344B2 (en) 2017-05-02
MX2013011583A (es) 2013-12-16
JO2958B1 (en) 2016-03-15
CA2832123A1 (en) 2012-10-11
WO2012136553A1 (en) 2012-10-11
ECSP13013006A (es) 2013-12-31
MY169452A (en) 2019-04-11
UY33985A (es) 2012-10-31
MX336057B (es) 2016-01-07

Similar Documents

Publication Publication Date Title
KR101937501B1 (ko) 치환된 2,3-디히드로이미다조[1,2-ｃ]퀴나졸린 염
CN107949557B (zh) 作为mIDH1抑制剂的2-芳基-和2-芳烷基-苯并咪唑类
HK1214169A1 (zh) 用於治疗癌症的瑞戈非尼和乙酰水杨酸的组合
JP2018524383A (ja) Ｍｉｄｈ１阻害剤としての縮合イミダゾール
JP7806119B2 (ja) 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用
CN114786674A (zh) Ahr抑制剂和pd1抑制剂抗体的组合及其在癌症治疗中的用途
CN108864101B (zh) 氘代sgx523 及其用途
RU2774838C2 (ru) Комбинация регорафениба и ингибиторов pd-1/pd-l1(2) для лечения рака
WO2016197981A1 (zh) 氘代的3-[(6-喹啉基)二氟甲基]-6-[(1-甲基)-4-吡唑基][1,2,4]三唑并[4,3-b]哒嗪及其应用
HK1195907B (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
HK40071759A (en) Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer
HK40015063A (en) Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20220103

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240105

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240105